Contraception
Volume 81, Issue 4 , Pages 275-280 , April 2010

Clinical pharmacokinetics and interaction of centchroman — A mini review

  • Jawahar Lal

      Affiliations

    • Corresponding Author InformationTel.: +91 522 2612411 18x4406; fax: +91 522 2623938/2623405.

Received 12 February 2009 ,Revised 12 November 2009 ,Accepted 19 November 2009.

References 

  1. Ray S, Kamboj V, Grover P, Kar A, Anand N. A process for the synthesis of 2,2-disubstituted-3,4-diphenylchromans. 1975;Indian Patent Specification No. 129187
  2. WHO . Proposed international nonproprietary names: List 69. WHO Drug Inf. 1993;7:87
  3. Nityanand S, Anand N. Centchroman: a nonsteroidal antifertility agent. FOGSI (Fed Obstet Gynaecol Soc, India) FOCUS. 1996;8–10
  4. Nityanand S. Centchroman: current status as a contraceptive. In: Proc X Indian Conf Family Welfare Voluntary Sterilization, Jimpur, Pondicherry, India, August 19–21. 1994;p. 41–42
  5. Kamboj VP, Ray S, Dhawan BN. Centchroman. Drugs Today. 1992;28:227–232
  6. Nityanand S, Wati C, Singh L, Srivastava JS, Kamboj VP. Clinical evaluation of centchroman: a new oral contraceptive. In:  Puri CP,  VanLook PFA editor. Hormone antagonists for fertility regulation. Bombay: Indian Soc Study Reprod Fert, India; 1988;p. 223–230
  7. Nityanand S, Kamboj VP, Wati C, et al. Contraceptive efficacy and safety of centchroman with biweekly-cum-weekly schedule. In:  Puri CP,  VanLook PFA editor. Current concepts in fertility regulation and reproduction. New Delhi: Wiley Eastern Ltd; 1994;p. 61–68
  8. Nityanand S, Gupta RC, Kamboj VP, Srivastava PK, Berry M. Centchroman: current status as a contraceptive. In:  Dawn SC,  Misra A editor. Indian progress in family welfare: Clinical research on maternal and child health and contraception. Calcutta: Dawn Books; 1995;p. 26–31
  9. Puri V, Kamboj VP, Chandra H, et al. Results of multicentric trial of centchroman. In:  Dhawan BN,  Agarwal KK,  Arora RB,  Parmar SS editor. Pharmacology for health in Asia. Allied Publishers: New Delhi; 1988;p. 439–447
  10. Rajpal M, Rajpal VK. Efficacy and safety of centchroman in clinical practice: a retrospective study. In: Proc X Indian Conf Family Welfare Voluntary Sterilization, Jimpur, Pondicherry, India, 19–21, August. 1994;p. 21
  11. Rajan R. Contraceptive and non-contraceptive benefits of centchroman. Asian J Obstet Gynaecol. 1996;1:65–71
  12. Rajan R. Contraceptive and non-contraceptive benefits of centchroman. In: Proceedings of the International Meeting on Safe Motherhood, Guwahati, India. 1996;p. 94–99
  13. Rajan R. Contraceptive and non-contraceptive benefits of centchroman. In:  Rajan R editors. Reproductive endocrinology. Jaypee Brothers: New Delhi; 1997;p. 487–497
  14. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev. 1984;36:245–276
  15. Grubb GS. Experimental methods of contraception. Curr Opin Obstet Gynecol. 1991;3:491–495
  16. Yuzpe AA. Post-coital contraception. In:  Corson SL,  Derman RJ,  Tyrer LB editor. Fertility control. Boston, MA: Little Brown and Company; 1985;p. 289–297
  17. Macgregor JJ, Jordan VC. Basic guide to the mechanism of antiestrogen action. Pharm Rev. 1998;50:151–196
  18. Kamboj VP, Kar AB, Ray S, Grover PK, Anand N. Antifertility activity of 3-4-trans-2,2-dimethyl-3-phenyl-4-[4-(β-pyrolidinoethoxy)phenyl]-7-methoxychromans. Indian J Exp Biol. 1971;9:103–105
  19. Kamboj VP, Setty BS, Chandra H, Roy SK, Kar AB. Biological profile of centchroman- a new post-coital contraceptive. Indian J Exp Biol. 1977;15:1141–1150
  20. Singh MM, Bhalla V, Wadhwa V, Kamboj VP. Effect of centchroman on tubal transport and pre-implantation embryonic developments in rats. J Reprod Fertil. 1986;76:317–324
  21. Singh MM, Kamboj VP. Fetal resorption in rats treated with an antiestrogen in relation to luteal phase nidatory estrogen secretion. Acta Endocr. 1992;126:444–450
  22. Singh MM, Sreenivasulu S, Kamboj VP. Duration of anti-implantation action of a triphenylethylene antiestrogen centchroman in adult female rats. J Reprod Fertil. 1994;100:367–374
  23. Indian Pharmacopoeia. In: Centchroman. Delhi: The Controller of Publications; 1996;p. 539–540
  24. The Merck Index . In:  Budavari S editors. Centchroman. 12th ed. Whitehouse Station, NJ: 7 Merck Co. Inc; 1996;p. 327
  25. Singh MM. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 2001;21:302–347
  26. Trivedi RN, Chauhan SC, Dwivedi A, Maitra SC, Kamboj VP, Singh MM. Time related effects of a triphenylethylene antiestrogen on estrogen induced changes in uterine weight, estrogen receptors and endometrial sensitivity in immature rats. Contraception. 1995;51:367–379
  27. Chauhan SC, Singh MM, Maitra SC, Kamboj VP. Inhibition of progesterone induced development of giant mitochondria in uterine glandular epithelial cells by an antiestrogen in rat. Contraception. 1996;54:259–264
  28. Singh MM, Chauhan SC, Maitra SC, Trivedi RN, Kamboj VP. Correlation of pinopod development on uterine luminal epithelial surface with hormonal events and endometrial sensitivity in rat. Eur J Endocr. 1996;135:107–117
  29. Singh MM, Trivedi RN, Chauhan SC, Srivastava VML, Kamboj VP. Uterine estradiol and progesterone receptor concentration, activities of certain antioxidant enzymes and dehydrogenases and histoarchitecture in relation to time of secretion of nidatory estrogen and high endometrial sensitivity in rat. J Steroid Biochem Mol Biol. 1996;59:215–224
  30. Bansode FW, Chauhan SC, Makke A, Singh MM. Uterine luminal epithelial alkaline phosphatase activity and pinopod development in relation to endometrial sensitivity in rat. Contraception. 1998;58:61–68
  31. CDRI . Centchroman: antineoplastic, antiestrogen. Drugs Fut. 1991;16:654
  32. Iyer SS. India launches the new weekly contraceptive pill. Drug News Perspect. 1991;4:228–229
  33. Misra NC, Nigam PK, Gupta R, Aggarwal AK, Kamboj VP. Centchroman—a nonsteroidal anticancer agent for advanced breast cancer—Phase II study. Int J Cancer. 1989;43:781–783
  34. Piggott JM. 3,4-Diarylchromans for treatment of dermatitis. Zymogenetics, Seattle, WA, US Patent 5451603.
  35. Labroo VM, Piggott JR, Bain SD, Methods for reducing bone loss using centchroman derivatives. Zymogenetics, Seattle, WA US Patent 5280040.
  36. Bryant HU, Dodge JA, Methods for lowering cholesterol and inhibiting smooth muscle proliferation, restenosis, endometriosis, and uterine fibroid disease. Eli Lilly, Indianapolis, IN US Patent 5407955.
  37. Nair RK, Sheyte TA, Munshi SR. Progestational and antiprogestational effects of centchroman in mouse and rabbit. Indian J Exp Biol. 1977;15:1157–1158
  38. Mehrotra PK, Nilsson BO. Ultrastructural effects of the nonsteroidal contraceptive centchroman on rat uterine luminal epithelium in early pregnancy. Int J Fertil. 1984;29:44–53
  39. Roy SN, Kumari GL, Modoiya K, Prakash V, Ray S. Induction of ovulation in human with centchroman, a preliminary report. Fertil Steril. 1976;27:1108–1110
  40. Singh MM, Bhalla V, Wadhwa V, Kamboj VP. Effect of centchroman on tubal transport and preimplantation embryonic development in rats. J Reprod Fert. 1986;76:317–324
  41. Labroo VM, Piggott JR, Bain SD. Methods for reducing bone loss using centchroman derivatives. Zymogenetics, Seattle, WA. US 5,280,040.
  42. Piggott JR. 3,4-Diarylchromans for treatment of dermatitis. Zymogenetics, Seattle, WA. US 5,451,603.
  43. Bryant HU, Dodge JA. Methods for lowering cholesterol and inhibiting smooth muscle proliferation, restenosis, endometriosis, and uterine fibroid disease. Eli Lilly Indianapolis, IN., US 5,407,955.
  44. Williams JP, McDonald JM, McKenna MA, Jordan SE, Radding W, Blair HC. Differential effects of tamoxifen-like compounds on osteoclastic bone degradation, H(+)-ATPase activity, calmodulin-dependent cyclic nucleotide phosphodiesterase activity, and calmodulin binding. J Cell Biochem. 1997;66:358–369
  45. Dwivedi A, Basu R, Chowdhury SR, Goyal N. Modulation of estrogen action during preimplantation period and in immature estradiol-primed rat uterus by anti-implantation agent, ormeloxifene. Contraception. 2005;71:458–464
  46. Paliwal JK, Gupta RC, Grover PK, Asthana OP, Srivastava JS, Nityanand S. High-performance liquid chromatography (HPLC) determination of centchroman in human serum, and application to single-dose pharmacokinetics. Pharm Res. 1989;6:1048–1051
  47. Lal J, Paliwal JK, Grover PK, Gupta RC. Simultaneous liquid chromatographic determination of centchroman and its 7-demethylated metabolite in serum and milk. J Chromatogr Biomed Appl. 1994;658:193–197
  48. Khurana M, Lal J, Kamboj M, Nityanand S, Kamboj VP, Gupta RC. Uptake of centchroman by human uterus. Clin Drug Invest. 2002;22:715–718
  49. Lal J, Asthana OP, Nityanand S, Gupta RC. Pharmacokinetics of centchroman in healthy female subjects after oral administration. Contraception. 1995;52:297–300
  50. Lal J, Nityanand S, Asthana OP, Gupta RC. Comparative bioavailability of two commercial centchroman tablets in healthy female subjects. Indian J Pharmacol. 1996;28:32–34
  51. Gupta RC, Lal J, Nityanand S, Asthana OP. Dose-related differences in serum concentration of centchroman in female volunteers. In: Proc XXIX Ann Conf Indian Pharmacol Soc, Hyderabad, India. 1996;
  52. Lal J, Nityanand S, Asthana OP, Gupta RC. Multiple-dose pharmacokinetics of centchroman in female volunteers. Indian J Pharmacol. 1998;30:120
  53. Gupta RC, Nityanand S, Asthana OP, Lal J. Pharmacokinetics of centchroman in nursing women and passage into breast milk. Clin Drug Invest. 1996;11:305–309
  54. Gupta RC, Nityanand S, Asthana OP, Lal J. Centchroman kinetics and disposition into breast milk. In: Proc 1st Ann Conf Indian Soc Chem Biol, Lucknow, India, 23–24 March. 1996;p. 93–100
  55. Khurana M, Paliwal JK, Kamboj VP, Gupta RC. Binding of centchroman as determined by charcoal adsorption method. Int J Pharm. 1999;197:109–114
  56. Ratna S, Chandra G, Ray S, Roy SK. Centchroman: binding with plasma proteins of rat, rabbit, guinea pig, and rhesus monkey. Drug Dev Res. 1991;24:285–291
  57. Agnihotri A, Srivastava AK, Kamboj VP. Characterization of centchroman binding protein in plasma of rhesus monkey (Macaca mulatta). J Med Primatol. 1996;25:53–56
  58. Srivastava AK, Agnihotri A, Kamboj VP. Binding of centchroman—a nonsteroidal antifertility agent in human plasma proteins. Experientia. 1984;40:465–466
  59. Lal J, Nityanand S, Asthana OP, Nagaraja NV, Gupta RC. Optimization of contraceptive dosage regimen of centchroman. Contraception. 2001;63:47–51
  60. Paliwal JK, Gupta RC. Tissue distribution and pharmacokinetics of centchroman a new nonsteroidal postcoital contraceptive agent and its 7-desmethyl metabolite in female rats after a single oral dose. Drug Metab Dispos. 1996;24:148–155
  61. Khurana M, Lal J, Singh MM, Paliwal JK, Kamboj VP, Gupta RC. Evaluation of interaction potential of certain concurrently administered drugs with pharmacological and pharmacokinetic profile of centchroman in rats. Contraception. 2002;66:47–56
  62. Ratna S, Roy SK, Ray S, et al. Centchroman: in vitro metabolism by rat liver homogenate. Drug Dev Res. 1986;7:173–178
  63. Kole PL, Ray S. Synthesis of trans-2,2-dimethyl-3-phenyl-4-(p-β-pyrrolidinoethoxy) phenyl-7-methoxy-(2-12C)chroman. J Labelled Compd Radiopharm. 1978;16:373–376
  64. Mishra NC, Ray S, Roy SK. Influence of centchroman on some hepatic microsomal enzymes in female rhesus monkeys. Med Sci Res. 1990;18:881–882
  65. Ganong WF. In: Review of Medical Physiology. California: Lange Medical Publications; 1985;p. 575
  66. Paliwal JK, Grover PK, Asthana OP, Nityanand S, Gupta RC. Excretion of centchroman in breast milk. Br J Clin Pharmacol. 1994;38:485–486
  67. Gupta RC, Paliwal JK, Nityanand S, Asthana OP, Lal J. Centchroman: a new nonsteroidal oral contraceptive in human milk. Contraception. 1995;52:301–305
  68. Atkinson HC, Begg EJ, Darlow BA. Guide to safety of drugs in human milk. In: Clinical Pharmacokinetics Drug Data Handbook. 4:Sydney: Adis Press; 1990;p. 125–164
  69. Khurana M, Lal J, Kamboj VP, Nityanand S, Gupta RC. Pharmacokinetic interaction of tetracycline with centchroman in healthy female volunteers. Drugs R D. 2003;4:293–299

☆ There was no funding provided for this study.

PII: S0010-7824(09)00516-2

doi: 10.1016/j.contraception.2009.11.007

Contraception
Volume 81, Issue 4 , Pages 275-280 , April 2010

Article Tools

* Image Usage & Resolution